aspirin has been researched along with Hemoglobinopathies in 3 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Hemoglobinopathies: A group of inherited disorders characterized by structural alterations within the hemoglobin molecule.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aspirin was shown to increase oxygen affinity of hemoglobin via acetylating lysine residues and its general acetylating activity on proteins such as histones makes it also an interesting candidate to activate fetal hemoglobin." | 5.34 | Medroxyprogesterone - valproic acid - aspirin. MVA regime to reduce transfusion associated mortality in late-term hemoglobinopathies. Hypothesis and rationale. ( Altinoz, MA; Carin, MN; Gedikoglu, G; Ozdilli, K, 2007) |
| "Aspirin was shown to increase oxygen affinity of hemoglobin via acetylating lysine residues and its general acetylating activity on proteins such as histones makes it also an interesting candidate to activate fetal hemoglobin." | 1.34 | Medroxyprogesterone - valproic acid - aspirin. MVA regime to reduce transfusion associated mortality in late-term hemoglobinopathies. Hypothesis and rationale. ( Altinoz, MA; Carin, MN; Gedikoglu, G; Ozdilli, K, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boucher, AA | 1 |
| Gurunathan, A | 1 |
| Taylor, JM | 1 |
| Ricci, KW | 1 |
| Vadivelu, S | 1 |
| Quinn, CT | 1 |
| Altinoz, MA | 1 |
| Ozdilli, K | 1 |
| Carin, MN | 1 |
| Gedikoglu, G | 1 |
| Everett, RB | 1 |
| Worley, RJ | 1 |
| MacDonald, PC | 1 |
| Chand, S | 1 |
| Gant, NF | 1 |
1 review available for aspirin and Hemoglobinopathies
| Article | Year |
|---|---|
Vascular reactivity to angiotensin II in human pregnancy.
Topics: Adolescent; Angiotensin II; Animals; Aspirin; Blood Pressure; Blood Volume; Dogs; Female; Haplorhini | 1978 |
2 other studies available for aspirin and Hemoglobinopathies
| Article | Year |
|---|---|
Hemoglobin Southampton complicated by cerebral ischemia, moyamoya, and hydroxyurea-induced methemoglobinemia.
Topics: Aspirin; Brain Ischemia; Child; Female; Hemoglobinopathies; Hemoglobins, Abnormal; Humans; Hydroxyur | 2019 |
Medroxyprogesterone - valproic acid - aspirin. MVA regime to reduce transfusion associated mortality in late-term hemoglobinopathies. Hypothesis and rationale.
Topics: Aspirin; Blood Transfusion, Intrauterine; Dose-Response Relationship, Drug; Drug Therapy, Combinatio | 2007 |